HealthFDA approves Johnson & Johnson’s Spravato for standalone depression treatmentmanamalive.comJanuary 21, 2025January 21, 2025 by manamalive.comJanuary 21, 2025January 21, 20250209 FDA approves Johnson & Johnson’s Spravato as a standalone therapy, marking a breakthrough for treatment-resistant depression and offering rapid relief to patients with unmet medical needs....